Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.
Aim(s): We aim at identifying signaling partners responsible of acquired resistance to treatments in order to develop drug combinations to prevent resistance occurence.
Materials and methods: We engineered NETs cell lines, BON-1 and QGP-1, resistant to a chemotherapeutic agent, Oxaliplatin, and to an mTor inhibitor, Everolimus, by chronically exposing them to the drugs. We are using microarray-based kinomics to obtain highthroughput kinase activity profiles from drug sensitive vs resistant cells.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano
To read results and conclusion, please login ...
Further abstracts you may be interested in